What Is ARA-290 (Cibinetide)? A Research Guide
ARA-290 (Cibinetide) explained at a research level. Learn what the peptide is, the pathways it is studied in, and how to verify quality. Supplied for laboratory and research use only in Australia.
What is ARA-290 (Cibinetide)?
ARA-290, also known as Cibinetide, is supplied by Pepology strictly for laboratory and research use only. It is not intended for use in humans or animals, and nothing in this guide describes such use. The purpose here is simply to explain what the molecule is at a research level and why it appears in the scientific literature.
At a structural level, ARA-290 is a short synthetic peptide. It is derived from the erythropoietin (EPO) protein, specifically from a region of the molecule known as helix B. Rather than reproducing the whole EPO protein, ARA-290 corresponds to a small linear sequence drawn from that region, which is why it is sometimes described in the literature as a helix B surface peptide.
Because it is built from only a handful of amino acid residues, ARA-290 is classified as a peptide rather than a full protein. It is often grouped with the non-erythropoietic derivatives of erythropoietin, meaning it is characterised for signalling behaviour that is considered separate from the classic red blood cell functions historically associated with EPO. In the wider peptide landscape it is catalogued alongside other compounds investigated in tissue and cellular models.
The structure at a glance
For researchers cataloguing a compound, a few high-level structural facts are worth noting. These describe what the molecule is at a laboratory level, not any effect it might have.
- Class: a short synthetic peptide, one of the non-erythropoietic erythropoietin derivatives.
- Origin: sequence derived from helix B of the erythropoietin (EPO) protein.
- Form: typically supplied as a lyophilised (freeze dried) powder for laboratory handling and reconstitution.
- Identity: confirmed in the laboratory by methods such as mass spectrometry, which check the molecule matches its stated sequence.
- Naming: ARA-290 and Cibinetide refer to the same research compound.
Why researchers study ARA-290
Interest in ARA-290 in preclinical and laboratory research comes largely from its relationship to the erythropoietin pathway. Erythropoietin has long been characterised for its role in red blood cell production, but researchers observed that certain protective signalling associated with EPO appeared to operate through a distinct receptor arrangement. ARA-290 was designed as a way to probe that second pathway without engaging the classic red blood cell axis.
In the literature, this second route is frequently described in terms of an innate repair receptor, understood as a heteromeric complex involving the erythropoietin receptor together with a shared beta common receptor subunit (CD131). ARA-290 is studied as a tool compound for investigating signalling through this proposed complex in cellular and animal models.
It is important to frame this correctly. These are research questions about receptor biology and cell signalling, explored in laboratory systems. The study of ARA-290 is about understanding a pathway, not about producing any outcome in a person or animal.
Pathways and models in the literature
The preclinical literature that mentions ARA-290 tends to cluster around a few themes, all of them mechanistic. Researchers have used it to examine how signalling through the proposed innate repair receptor influences inflammatory and cellular processes in controlled models.
Commonly referenced areas of research interest include inflammatory signalling cascades, neuronal and neuro-immune cell behaviour, and models of tissue stress and repair. In each case the compound functions as an experimental probe, a way to switch on or interrogate a specific pathway so that its downstream biology can be measured in vitro or in animal studies.
None of this establishes any use or effect outside the laboratory. When ARA-290 appears in a study, it is being used to answer a scientific question about how a pathway works. It is not evidence of any effect in a person or animal, and Pepology supplies it for laboratory and research use only.
How ARA-290 is characterised in the laboratory
Whatever pathway a peptide is studied in, the first practical question for any researcher is whether the material in the vial genuinely matches its label. For a compound like ARA-290, that means identity and purity are confirmed by analytical testing rather than assumed.
Identity testing confirms that the molecule present is the intended peptide sequence. This is typically done using mass spectrometry, which measures the molecular mass and compares it against the expected value for the sequence. Purity testing, usually by high performance liquid chromatography (HPLC), separates a sample into its components and reports how much of the batch is the target compound versus other species. Together these two analyses describe what the material actually is and how clean it is.
Pepology speaks about these tests in general terms on purpose. We do not publish invented figures. The real results for any given batch live on that batch's certificate of analysis, which is the document that ties a specific production run to its measured results.
How to verify quality
Every batch of research peptides sold by Pepology is third-party lab tested by Novagen Laboratories, and each batch is accompanied by a certificate of analysis that customers can verify independently. A certificate is only meaningful if you can connect it to the vial in front of you, so it is worth checking a few things every time.
Use this short checklist when you receive ARA-290 or any research peptide.
- Find the lot or batch number on the certificate of analysis, then confirm it matches the number printed on the vial. They must be identical.
- Check that the compound name on the certificate reads ARA-290 (Cibinetide), matching what you ordered.
- Look for identity confirmation, for example by mass spectrometry, and a purity result reported by HPLC.
- Confirm the testing was carried out by an independent third-party laboratory, Novagen Laboratories, rather than the seller alone.
- Verify the certificate independently rather than taking a screenshot at face value.
Sourcing ARA-290 (Cibinetide) in Australia
Pepology is an Australian, Gold Coast owned and operated retailer of research peptides. Buying locally means your order is handled within Australia and backed by third-party testing through Novagen Laboratories, with a verifiable certificate of analysis for every batch.
When choosing where to source a research compound, the fundamentals matter more than marketing. Look for a supplier that tests every batch with an independent laboratory, that lets you match the lot number on the certificate to the vial, and that is transparent about what its analytical testing does and does not cover. That is the standard Pepology aims to meet on every order.
To reiterate, ARA-290 (Cibinetide) is supplied for laboratory and research use only. It is not for human or animal use. If you are stocking a research programme, you can review the product listing or explore the wider catalogue below.
Frequently asked questions
What is ARA-290 (Cibinetide)?
ARA-290, also called Cibinetide, is a short synthetic peptide derived from helix B of the erythropoietin (EPO) protein. It is one of the non-erythropoietic erythropoietin derivatives and is studied in preclinical and laboratory research as a tool for investigating signalling through the proposed innate repair receptor. Pepology supplies it strictly for laboratory and research use only.
Is ARA-290 (Cibinetide) for human or animal use?
No. ARA-290 (Cibinetide) is supplied for laboratory and research use only. It is not for human or animal use, and we do not provide any dosing, administration or usage guidance. Nothing about the compound should be interpreted as suitable for use in a person or animal.
Why do researchers study ARA-290?
Research interest centres on its relationship to the erythropoietin pathway. Because ARA-290 is derived from EPO but is non-erythropoietic, it is used in laboratory and animal models as a probe to investigate signalling through a proposed innate repair receptor complex, including inflammatory and cellular pathways. This is mechanistic research and is not evidence of any effect outside the laboratory.
How do I verify the quality of ARA-290 (Cibinetide)?
Every Pepology batch is third-party lab tested by Novagen Laboratories and comes with a certificate of analysis. Check that the lot number on the certificate matches the number on the vial, that identity is confirmed (for example by mass spectrometry) and that purity is reported by HPLC, then verify the certificate independently rather than relying on a screenshot.
How is ARA-290 tested for identity and purity?
Identity is typically confirmed using mass spectrometry, which checks the molecular mass matches the expected peptide sequence, while purity is measured by high performance liquid chromatography (HPLC), which reports how much of the batch is the target compound. Pepology describes these test types in general terms and publishes the actual measured results on each batch certificate rather than quoting invented figures.
Where can I buy ARA-290 (Cibinetide) in Australia?
You can source ARA-290 (Cibinetide) from Pepology, an Australian, Gold Coast owned and operated retailer of research peptides. Every batch is third-party lab tested by Novagen Laboratories with a verifiable certificate of analysis, and all compounds are supplied for laboratory and research use only, not for human or animal use.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.